1.Wei Y, Ke X, Yu J, et al. Clinical and genomic analyses of neuroendocrine neoplasms of the breast. Modern pathology :an official journal of the United States and Canadian Academy of Pathology, Inc. 2022;35(4):495-505.
2.Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer:ASCO/CAP Guideline Update. Journal of clinical oncology :official journal of the American Society of Clinical Oncology. 2020;38(12):1346-1366.
3.Schrodi S, Braun M, Andrulat A, et al. Outcome of breast cancer patients with low hormone receptor positivity:analysis of a 15-year population-based cohort. Annals of oncology :official journal of the European Society for Medical Oncology. 2021;32(11):1410-1424.
4.Strickler JH, Yoshino T, Graham RP, Siena S, Bekaii-Saab T. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer:A Review. JAMA oncology. 2022.
5.Zhang H, Katerji H, Turner BM, Hicks DG. HER2-Low Breast Cancers. American journal of clinical pathology. 2022;157(3):328-336.
6.Cai L, Yan K, Bu H, et al. Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope:a multi-institutional ring study. Histopathology. 2021;79(4):544-555.
7.Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer:results from the FinHER trial. Annals of oncology :official journal of the European Society for Medical Oncology. 2014;25(8):1544-1550.
8.Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ:A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in cancer biology. 2018;52(Pt 2):16-25.
9.Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer:clinical utility in an era of checkpoint inhibition. Annals of oncology :official journal of the European Society for Medical Oncology. 2021;32(10):1236-1244.